AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8751230 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment II (B 10 ml, OT 750 mg, M 400 mg, q.i.d. for 7 days)
Number of subjects: 306
Study 8751230 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment III (B 10 ml, OT 500 mg, M 400 mg, q.i.d. for 10 days)
Number of subjects: 306
Study 8751230 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after H pylori eradication
Number of subjects: 306
Study 1679482 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine collection from disposable nappies
Number of subjects: 45
Study 6951254 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (1.1 mM solution)
Number of subjects: 0
Study 6951254 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (1.1 mM solution)
Number of subjects: 0
Study 6951254 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate (1.1 mM solution)
Number of subjects: 0
Study 6951254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31271198 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-year lifestyle intervention involving diet and physical activity
Number of subjects: 1128
Study 31271198 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1128
Study 29023938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention using Beers Criteria and STOPP criteria
Number of subjects: 248
Study 25668557 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% wt/wt ethanol solution
Number of subjects: 1460
Study 25668557 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (control group)
Number of subjects: 1460
Study 23864339 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-acyl ghrelin (DAG) infusion (3 and 10 μg DAG/kg per h)
Number of subjects: 8
Study 23864339 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-acyl ghrelin (DAG) infusion
Number of subjects: 8
Study 23864339 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-acyl ghrelin (DAG) infusion during hyperinsulinemic-euglycemic clamp (HEC)
Number of subjects: 8
Study 23864339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21573987 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 40
Study 21573987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19774810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy extracorporeal shock wave therapy (ESWT) - 6000 impulses (ED+ 0.78 mJ/mm2) in 3 sessions under local anaesthesia
Number of subjects: 40
Study 19774810 — intervention group
Group type: COMPARATOR
Intervention: Low-energy extracorporeal shock wave therapy (ESWT) - 6000 impulses (ED+ 0.33 mJ/mm2) under local anaesthesia
Number of subjects: 40
Study 17315050 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory-dose doxycycline (Oracea) - 40 mg capsule containing 30 mg immediate-release and 10 mg delayed-release doxycycline beads, taken once daily.
Number of subjects: 13000000
Study 17315050 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 13000000
Study 15235901 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim, 5 microg/kg day)
Number of subjects: 48
Study 15235901 — intervention group
Group type: COMPARATOR
Intervention: G-CSF plus oral antibiotics (amoxicillin/clavulanate plus ciprofloxacin)
Number of subjects: 48
Study 12370860 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH alone
Number of subjects: 16
Study 12370860 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus arginine (ARG)
Number of subjects: 16
Study 12370860 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIH withdrawal
Number of subjects: 16
Study 12370860 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone (Control)
Number of subjects: 16
Study 12370860 — intervention group
Group type: COMPARATOR
Intervention: GHRH plus arginine (ARG) (Control)
Number of subjects: 16
Study 10689662 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave 2 average alcohol consumption
Number of subjects: 596
Study 7649670 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial triggered ventricular pacing (VDD)
Number of subjects: 17
Study 7649670 — intervention group
Group type: COMPARATOR
Intervention: Rate responsive ventricular pacing (VVIR)
Number of subjects: 17
Study 2588760 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN 120 mg ret.
Number of subjects: 40
Study 2588760 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN 120 mg plus Diltiazem 120 mg ret.
Number of subjects: 40
Study 421966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortagesic
Number of subjects: 2
Study 421966 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 2
Study 31130288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole, 1 mg/day
Number of subjects: 82
Study 28595614 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Denmark Region PEWS model
Number of subjects: 14000
Study 28595614 — intervention group
Group type: COMPARATOR
Intervention: Bedside PEWS model
Number of subjects: 14000
Study 25575764 — intervention group
Group type: EXPERIMENTAL
Intervention: SOL (S-1 40-60 mg bid + oral LV 25 mg bid for 1 week + oxaliplatin 85 mg/m² on day 1, every 2 weeks)
Number of subjects: 107
Study 25575764 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 107
Study 25575764 — intervention group
Group type: EXPERIMENTAL
Intervention: SOL
Number of subjects: 107
Study 24565088 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.4, preload of 15 mL.kg(‐1)
Number of subjects: 48
Study 24565088 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution, preload of 30 mL.kg(‐1)
Number of subjects: 48
Study 24565088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 22338037 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient choline intake in postmenopausal women
Number of subjects: 664
Study 22338037 — intervention group
Group type: COMPARATOR
Intervention: Choline intake in children, men, or premenopausal women
Number of subjects: 664
Study 20009604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture retained by a prefabricated bar
Number of subjects: 10
Study 20009604 — intervention group
Group type: COMPARATOR
Intervention: Mandibular overdenture retained by a cast bar
Number of subjects: 10
Study 17465506 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental group (Gln and rhGH), n = 22
Number of subjects: 42
Study 15479124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipoproteinemia patients
Number of subjects: 134
Study 15479124 — intervention group
Group type: COMPARATOR
Intervention: Normolipidemic controls
Number of subjects: 134
Study 11479493 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 110
Study 11479493 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 110
Study 9914669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus-item expectancy manipulation
Number of subjects: 0
Study 7774317 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (behavioral medicine counseling)
Number of subjects: 91
Study 7774317 — intervention group
Group type: COMPARATOR
Intervention: Monitoring control group
Number of subjects: 91
Study 7774317 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment control group
Number of subjects: 91
Study 3171220 — intervention group
Group type: EXPERIMENTAL
Intervention: UVC radiation exposure
Number of subjects: 8
Study 3171220 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB radiation exposure
Number of subjects: 8
Study 30983609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical hydroquinone 4% and fractional CO2 laser
Number of subjects: 40
Study 30983609 — intervention group
Group type: COMPARATOR
Intervention: Topical hydroquinone 4%
Number of subjects: 40
Study 29111457 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded inferior oblique anterior transposition (IOAT); sutured at the level of the inferior rectus and 2 mm posterior for less DVD
Number of subjects: 37
Study 29111457 — intervention group
Group type: COMPARATOR
Intervention: Ungraded inferior oblique anterior transposition (IOAT); both inferior oblique muscles sutured at the inferior rectus level
Number of subjects: 37
Study 25300285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardi04 yogurt (300 ml milk fermented with L. helveticus)
Number of subjects: 41
Study 25300285 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt (300 ml artificially acidified milk)
Number of subjects: 41
Study 23381483 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic luggage screening task (ASD group)
Number of subjects: 0
Study 23381483 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic luggage screening task (Control group)
Number of subjects: 0
Study 21501083 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus group
Number of subjects: 42
Study 21501083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 21501083 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus group (moderate and severe)
Number of subjects: 42
Study 21501083 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus group (severe)
Number of subjects: 42
Study 18444196 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive program
Number of subjects: 44
Study 18444196 — intervention group
Group type: COMPARATOR
Intervention: Traditional written material (Control)
Number of subjects: 44
Study 16540839 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg x kg(‐1) body mass
Number of subjects: 11
Study 16540839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 14511730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid etching
Number of subjects: 216
Study 14511730 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion
Number of subjects: 216
Study 14511730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating
Number of subjects: 216
Study 14511730 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating with silanization
Number of subjects: 216
Study 14511730 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling
Number of subjects: 216
Study 10699135 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Steps Program (HS) intervention group
Number of subjects: 5565
Study 10699135 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 5565
Study 9170475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 101
Study 9170475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous study drug)
Number of subjects: 101
Study 8251275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine
Number of subjects: 0
Study 8251275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 0
Study 8251275 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 3532353 — intervention group
Group type: EXPERIMENTAL
Intervention: Various new and commercially available drugs, surgery, and/or radiation therapy
Number of subjects: 1087
Study 29846142 — intervention group
Group type: EXPERIMENTAL
Intervention: IRR10 (10 s inter-repetition rest)
Number of subjects: 30
Study 29846142 — intervention group
Group type: EXPERIMENTAL
Intervention: IRR20 (20 s inter-repetition rest)
Number of subjects: 30
Study 29846142 — intervention group
Group type: COMPARATOR
Intervention: CR (continuous repetitions)
Number of subjects: 30
Study 26859091 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS
Number of subjects: 77
Study 26859091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 23723435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic musical training
Number of subjects: 45
Study 23723435 — intervention group
Group type: COMPARATOR
Intervention: Music playing in the background (Control Group 1)
Number of subjects: 45
Study 23723435 — intervention group
Group type: COMPARATOR
Intervention: No music and no training (Control Group 2)
Number of subjects: 45
Study 22948092 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest bathing (7-day/7-night trip to a broad-leaved evergreen forest)
Number of subjects: 24
Study 22948092 — intervention group
Group type: COMPARATOR
Intervention: City area control group
Number of subjects: 24
Study 22948092 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest bathing
Number of subjects: 24
Study 20307802 — intervention group
Group type: EXPERIMENTAL
Intervention: Movie montage with smoking scenes
Number of subjects: 100
Study 20307802 — intervention group
Group type: COMPARATOR
Intervention: Movie montage without smoking scenes
Number of subjects: 100
Study 20307802 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to smoking in movies
Number of subjects: 100
Study 20307802 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of nicotine dependence
Number of subjects: 100
Study 20307802 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation stage of change
Number of subjects: 100
Study 20307802 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontemplation stage of change
Number of subjects: 100
Study 20307802 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 100
Study 20307802 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching montage with smoking scenes
Number of subjects: 100
Study 18346292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 55
Study 18346292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16613306 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD)
Number of subjects: 200
Study 16613306 — intervention group
Group type: COMPARATOR
Intervention: No CAD (control)
Number of subjects: 200
Study 12925071 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant RCT
Number of subjects: 805
Study 12925071 — intervention group
Group type: COMPARATOR
Intervention: Postoperative RCT
Number of subjects: 805
Study 11232964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB
Number of subjects: 20
Study 11232964 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB
Number of subjects: 20
Study 9192927 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Plan and booklet on self-management plus supply of prednisone and antibiotics from GP
Number of subjects: 56
Study 9192927 — intervention group
Group type: COMPARATOR
Intervention: Usual care from GP
Number of subjects: 56
Study 1555312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal splints inserted for 7 days
Number of subjects: 100
Study 1555312 — intervention group
Group type: COMPARATOR
Intervention: No splints (control group)
Number of subjects: 100
Study 2861791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal luteinising hormone releasing hormone (1200 micrograms/day for 28 days)
Number of subjects: 40
Study 2861791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 30396037 — intervention group
Group type: EXPERIMENTAL
Intervention: OHES + ART (n=39)
Number of subjects: 78
Study 30396037 — intervention group
Group type: COMPARATOR
Intervention: ART (n=39)
Number of subjects: 78
Study 30249583 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT (Web-based program + 12 face-to-face sessions of 45 minutes each)
Number of subjects: 40
Study 30249583 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 40
Study 30249583 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT (follow-up at week 24)
Number of subjects: 40
Study 30249583 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT (posttreatment at week 12)
Number of subjects: 40
Study 26807502 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega 3-PUFA supplementation
Number of subjects: 205
Study 24479817 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 77
Study 24479817 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 77
Study 21448637 — intervention group
Group type: EXPERIMENTAL
Intervention: LED curing unit with two-component self-etching primers
Number of subjects: 500
Study 21448637 — intervention group
Group type: EXPERIMENTAL
Intervention: QTH curing unit with two-component self-etching primers
Number of subjects: 500
Study 21448637 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component self-etching primers
Number of subjects: 500
Study 21448637 — intervention group
Group type: COMPARATOR
Intervention: Acid-etching method
Number of subjects: 500
Study 19092677 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional stimulation with high intensity
Number of subjects: 19
Study 19092677 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional stimulation with large anode to small cathode
Number of subjects: 19
Study 19092677 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional stimulation with small anode to large cathode
Number of subjects: 19
Study 19092677 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense stimulation
Number of subjects: 19
Study 19092677 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller electrode size
Number of subjects: 19
Study 19092677 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying intensity and electrode geometry
Number of subjects: 19
Study 17687719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluticasone propionate and salmeterol, 500/100 microg daily (group 1; n = 52)
Number of subjects: 105
Study 17687719 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone, 1000 microg daily, and salbutamol inhaler, 800 microg daily (group 2; n = 53)
Number of subjects: 105
Study 15633616 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 to 400 mg/d)
Number of subjects: 0
Study 15633616 — intervention group
Group type: COMPARATOR
Intervention: AV node radiofrequency ablation (RFA) and permanent His-bundle pacing
Number of subjects: 0
Study 11800586 — intervention group
Group type: EXPERIMENTAL
Intervention: DPPD
Number of subjects: 51
Study 11800586 — intervention group
Group type: COMPARATOR
Intervention: PPD
Number of subjects: 51
Study 9732379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg)
Number of subjects: 16
Study 9732379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (7.5 to 30 mg)
Number of subjects: 16
Study 9732379 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 16
Study 9732379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 16
Study 8064214 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked marijuana
Number of subjects: 8
Study 8064214 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 8
Study 8064214 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive-interval schedule performance
Number of subjects: 8
Study 3353895 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite avoidance measures (including liquid nitrogen application to mattresses and carpets)
Number of subjects: 21
Study 3353895 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite avoidance measures
Number of subjects: 21
Study 3353895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 31003676 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure using vaccaria seeds
Number of subjects: 58
Study 31003676 — intervention group
Group type: COMPARATOR
Intervention: Placebo auricular acupressure using vaccaria seeds
Number of subjects: 58
Study 28592234 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded Marevan® (Uniao Quimica/Farmoquimica)
Number of subjects: 0
Study 28592234 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic warfarin (Uniao Quimica Farmaceutica Nacional)
Number of subjects: 0
Study 28592234 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic warfarin (Laboratorio Teuto Brasileiro)
Number of subjects: 0
Study 25740387 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel combined with cetuximab (arm A)
Number of subjects: 140
Study 25740387 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel combined with cixutumumab (arm B)
Number of subjects: 140
Study 25740387 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel combined with both cetuximab and cixutumumab (arm C)
Number of subjects: 140
Study 25740387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment or standard care)
Number of subjects: 140
Study 23497452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg plus Anastrozole 1 mg/day for 14 to 21 days (F + A)
Number of subjects: 121
Study 23497452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg plus Anastrozole placebo (F)
Number of subjects: 121
Study 23497452 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole alone (A)
Number of subjects: 121
Study 23497452 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (F, F + A, A)
Number of subjects: 121
Study 22020892 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rest
Number of subjects: 0
Study 22020892 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonant voice exercise
Number of subjects: 0
Study 22020892 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous speech
Number of subjects: 0
Study 19301041 — intervention group
Group type: COMPARATOR
Intervention: rhBMP-2
Number of subjects: 0
Study 16785262 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (letrozole 2.5 mg daily from cycle days 2 to 8)
Number of subjects: 45
Study 16785262 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen priming with aromatase inhibitor and hCG (1250 IU s.c. on cycle day 2)
Number of subjects: 45
Study 16785262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no other pretreatment)
Number of subjects: 45
Study 15385877 — intervention group
Group type: EXPERIMENTAL
Intervention: AGF platelet gel
Number of subjects: 84
Study 15385877 — intervention group
Group type: COMPARATOR
Intervention: Control (no AGF)
Number of subjects: 84